Comparative Pharmacology
Head-to-head clinical analysis: IFEX versus VIVIMUSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFEX versus VIVIMUSTA.
IFEX vs VIVIMUSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IFEX (ifosfamide) is an alkylating agent that crosslinks DNA strands, inhibiting DNA synthesis and transcription. It requires hepatic activation via CYP3A4 to form active metabolites (ifosfamide mustard and acrolein).
VIVIMUSTA is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
1.2 g/m2 intravenously daily for 5 consecutive days every 3 weeks, or 5 g/m2 as a 24-hour continuous infusion every 3 weeks.
100 mg/m2 intravenously over 30 minutes on days 1-3 of a 21-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min).
Renal: approximately 50-70% of the administered dose is excreted in urine as unchanged drug; biliary/fecal excretion is minimal, accounting for less than 5%.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category C
Category C
Alkylating Agent
Alkylating Agent